Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon, Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan.
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon, Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan.
Res Vet Sci. 2020 Dec;133:106-110. doi: 10.1016/j.rvsc.2020.08.019. Epub 2020 Sep 2.
The effects of different doses of orally administered sildenafil on pulmonary haemodynamics in dogs with pulmonary hypertension (PH) have not been documented in an invasive and quantitative manner. In this study, we examined the effects of oral sildenafil using a canine model of chronic embolic PH (CEPH). This CEPH model was created by repeatedly injecting microspheres through a catheter into the pulmonary artery under general anaesthesia at regular weekly intervals over several months. The CEPH dogs received 1, 2 or 4 mg/kg of sildenafil orally twice a day for seven days. Then, haemodynamic measurements including pulmonary artery pressure (PAP), systemic artery pressure (SAP), pulmonary artery wedge pressure (PAWP), right atrial pressure (RAP) and cardiac output (CO) were obtained after seven days of sildenafil administration via right heart catheterisation and oscillometric blood pressure measurements. Sildenafil was well tolerated in this study. Sildenafil administered at doses of 2 and 4 mg/kg significantly decreased systolic PAP compared with before administration. In addition, all doses of sildenafil significantly decreased the mean and diastolic PAP. Furthermore, 4 mg/kg of sildenafil significantly decreased PAP compared with 1 mg/kg. Sildenafil also significantly decreased pulmonary vascular resistance without notable changes in SAP or systemic vascular resistance. The PAWP, RAP and CO did not increase significantly at any doses. In conclusion, the oral administration of sildenafil to CEPH models decreased PAP in a dose-dependent manner.
不同剂量的口服西地那非对肺动脉高压(PH)犬肺血流动力学的影响尚未以侵入性和定量方式记录。在这项研究中,我们使用慢性栓塞性 PH(CEPH)犬模型检查了口服西地那非的效果。该 CEPH 模型是通过在全身麻醉下,每隔几周通过导管将微球反复注入肺动脉而创建的,持续数月。CEPH 犬每天口服 1、2 或 4 mg/kg 的西地那非两次,持续 7 天。然后,通过右心导管插入术和示波血压测量获得血流动力学测量值,包括肺动脉压(PAP)、体动脉压(SAP)、肺动脉楔压(PAWP)、右心房压(RAP)和心输出量(CO)。在这项研究中,西地那非耐受良好。与给药前相比,2 和 4 mg/kg 的西地那非剂量显著降低收缩压 PAP。此外,所有剂量的西地那非均显著降低平均和舒张压 PAP。此外,4 mg/kg 的西地那非与 1 mg/kg 的西地那非相比,PAP 显著降低。西地那非还显著降低肺动脉阻力,而 SAP 或全身血管阻力无明显变化。在任何剂量下,PAWP、RAP 和 CO 均未显著增加。总之,CEPH 模型口服西地那非可降低 PAP,呈剂量依赖性。